Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163014 | 0.89 | TBK1 (0.50) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20163092 | 0.88 | GPR119 (0.48) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20163029 | 0.85 | GPR119 (0.44) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20163110 | 0.85 | USP30 (0.46) | CKS1BSKP1SKP2GPR119USP30 | |
| SCHEMBL20163139 | 0.84 | HDAC1 (0.41) | CKS1BSKP1SKP2GPR119USP30 | |
| SCHEMBL20163021 | 0.78 | CKS1B (0.45) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20181514 | 0.78 | HDAC1 (0.56) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20163146 | 0.78 | GPR119 (0.42) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20163084 | 0.75 | HDAC3 (0.46) | CKS1BSKP1SKP2GPR119TBK1 | |
| SCHEMBL20163111 | 0.75 | ABCB1 (0.43) | CKS1BSKP1SKP2GPR119RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| EP-3544969-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018098296-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | CKS1B 366/4885SKP1 1856/4885SKP2 110/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | CKS1B 363/4885SKP1 1658/4885SKP2 126/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CKS1B 246/4885SKP1 1802/4885SKP2 211/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | CKS1B 573/4885SKP1 1022/4885SKP2 57/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CKS1B 436/4885SKP1 1189/4885SKP2 72/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CKS1B 246/4885SKP1 1802/4885SKP2 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.